Company Overview

Cartesian Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-engineered cell therapies for the treatment of autoimmune diseases. The company operates within the biotechnology and biopharmaceutical industries, with a strategic emphasis on advancing non-viral, mRNA-based cell therapy platforms. Its core approach is designed to deliver targeted immune modulation while avoiding the permanent genetic modification associated with DNA-based gene therapies.

The company’s primary revenue drivers are its internally developed clinical-stage therapeutic candidates rather than commercial product sales, as it has not yet brought a product to market. Cartesian Therapeutics serves patients with serious autoimmune and inflammatory diseases, with an initial focus on conditions with high unmet medical need. The company traces its origins to Selecta Biosciences, Inc., which underwent a strategic transformation and rebranding to Cartesian Therapeutics in 2023 following asset divestitures and a renewed focus on RNA-based cell therapy technologies.

Business Operations

Cartesian Therapeutics’ operations are centered on the research, development, and clinical advancement of its proprietary Descartes™ platform, which uses mRNA to engineer patient-derived T cells without permanent genome modification. The company’s lead programs target autoimmune indications, including myasthenia gravis and other antibody-mediated diseases. Revenue generation is currently limited to collaboration-related activities and interest income, with no approved commercial therapies as of the latest public disclosures.

The company operates primarily in the United States, with clinical trial activities conducted through third-party clinical research organizations and academic medical centers. Cartesian Therapeutics controls its core intellectual property and development programs internally, while manufacturing, clinical operations, and certain research activities rely on specialized external partners. No material joint ventures have been publicly disclosed based on available filings.

Strategic Position & Investments

Strategically, Cartesian Therapeutics is focused on advancing its mRNA-engineered cell therapy candidates through mid-stage clinical development, with the goal of demonstrating improved safety, repeat dosing potential, and scalability relative to traditional viral-based CAR-T therapies. Growth initiatives are concentrated on expanding clinical data for its lead assets and selectively advancing additional autoimmune indications using its existing platform.

The company has made targeted investments in its internal pipeline rather than pursuing large-scale acquisitions. Its strategic positioning emphasizes differentiation through transient mRNA expression, which management believes may reduce long-term safety risks. Public disclosures do not indicate ownership of major non-core subsidiaries or a diversified investment portfolio; the company remains tightly focused on therapeutic development. Data inconclusive based on available public sources regarding additional undisclosed strategic investments.

Geographic Footprint

Cartesian Therapeutics is headquartered in the United States, with its principal executive offices located in Massachusetts. Its operational footprint is primarily domestic, encompassing corporate management, research oversight, and regulatory activities. Clinical trials may involve investigational sites in multiple regions, but these are conducted through contracted institutions rather than permanent international facilities.

International presence is currently limited, with no significant standalone commercial or manufacturing operations outside the United States disclosed in public filings. The company’s global influence is primarily indirect, achieved through participation in internationally recognized clinical research standards and regulatory frameworks.

Leadership & Governance

Cartesian Therapeutics is led by an executive team with experience in biotechnology, pharmaceuticals, and capital markets. The leadership emphasizes disciplined capital allocation, platform-driven innovation, and a focus on autoimmune disease biology. Governance is overseen by a board of directors with backgrounds in life sciences, finance, and corporate strategy.

Key executives include:

• Carsten Brunn, Ph.D. – President and Chief Executive Officer
• Sean A. McClain – Chief Financial Officer
• Michael F. Singer, M.D. – Chief Medical Officer
• Ashleigh Palmer – Chief Operating Officer

The company’s leadership philosophy centers on advancing differentiated therapies through rigorous clinical validation while maintaining financial and operational flexibility.

Verification Requirements